ClinicalTrials.gg
RecruitingNCT07083089SAPHIRUpdated Dec 9, 2025

Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR)

An interventional study of Thorough Hearing assessment in Mild Cognitive Impairment (MCI) Amnestic, Parkinson Disease (PD) and Healthy Participants, sponsored by Cilcare SAS. Recruiting at 4 sites in France. Open to participants aged 50 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Cilcare SAS · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2025, registered Jul 2025).
  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
309
Allocation
Non-randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 189 studies in Cognitive Dysfunction with a site in France — 52 open to participants now, 60 under way, 6 of them phase 3. Cognitive Dysfunction · France.

Planned enrollment
25th of 139
309 · median 88
Started
2025
with 20 others
No phase
104 of 189
32 open now
Primary completion
2026-12
later than 23 of 59 live
Registered
178th of 189
by date

Among the 189 studies in Cognitive Dysfunction with a site in France, this one is the 25th largest by planned enrollment of the 139 interventional ones that give a count, is one of 21 that started in 2025, is one of 104 with no phase, reaches primary completion later than 23 of the 59 other live ones, and was the 178th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

52 of the 189 studies in Cognitive Dysfunction with a site in France are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Cognitive Dysfunction with a site in France, or all of them as a file.
02

Study summary

The study aims to phenotype hearing in patients with early stage of neurodegenerative disorders to explore the prevalence of various hearing disorders in comparison to a control population. Specific focus is made on patients with speech-in-noise intelligibiltiy deficit despite normal tonal audiograms referred to as hidden hearing loss, with potential identification of associated biomarkers.

Read the detailed description

A wide battery of subjective and objective hearing tests is performed on the subjects including tonal and vocal audiometry (in silence and in noise), DPOAE, acoustic reflex and electrophysiology recordings (auditory brainstem response, electrocochleography). Hearing tests are correlated to collected disease parameters and blood markers.

03

Conditions studied

  • Mild Cognitive Impairment (MCI) Amnestic
  • Parkinson Disease (PD)
  • Healthy Participants

Keywords

  • hearing phenotype
  • audiometry
  • speech-in-noise intelligibility
  • electrophysiology
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: All subjects

  1. Man or woman aged between 50 and 85 years old at baseline.
  2. Fluent in French (native language)
  3. Be considered as reliable and capable of adhering to the protocol, according to the judgment of the investigator (understanding of the information included in the protocol, and requests to realize the investigations, good general health and able to move around).
  4. Affiliated to Public Health Insurance (Sécurité Sociale)
  5. Signed and dated form.

For amnestic MCI:

Diagnosis of amnestic MCI, according to international diagnosis criteria (NIA-AA, 2011) with ≥23 or MMSE>24.Patients must exhibit predominantly cognitive impairments in episodic memory, defined by a score on the RL/RI 16-item test with a free recall score of less than 18/48 and a total recall score of less than 40/48.

For Parkinson Patients:

Established clinical diagnosis of Parkinson's disease according to Postuma et al. 2015 with bradykinesia associated with resting tremor or rigidity, no exclusion criteria or red flag with MOCA ≥23.

For controls:

No diagnosis of neurological disease such as Parkinson's disease or MCI associated or not with Alzheimer's disease Displays normal cognitive status with a MoCA score ≥ 26.

Non-inclusion criteria:

  1. Known hearing pathologies leading to conductive hearing loss (otosclerosis, a diagnosed pathology of the ear canal, tympanic membrane, ossicles or 3rd window), otitis, congenital deafness or sensorineural hearing loss associated to Menière's disease.
  2. Psychiatric diseases other than neurodegenerative etiology
  3. Neurological or neurovascular disorders (Stroke, epilepsy, dementia)
  4. Motor complications that could interfere with audiological assessment
  5. Known Diagnosis of type 2 diabetes
  6. Alcohol or drug addiction
  7. Cochlear implant
  8. Known ototoxic drug therapy:

    1. Antibiotics: Aminosides IV, macrolides, tetracyclines in the last 15 days prior to inclusion
    2. Antipaludic drugs: quinine, hydroxychloroquine, chloroquine in the last 15 days prior to inclusion
    3. Platinum-based chemotherapy at any time prior to inclusion.
    4. Loop diuretics: furosemide (max oral dose of ≤60mg/day) at inclusion and during the study.
    5. Salicylate derivatives at high dose (Kardegic allowed at dose ≤320mg/day) at inclusion and during the study.
  9. History of otological surgical act.
  10. On-going pregnancy or breast-feeding.
  11. Adults protected by law: in vulnerable social situations or unable to express consent.
  12. Under another protocol that may interfere with the analysis of the results.

Exclusion Criteria:

Patients will be excluded from the study if one or more of the following criteria are applicable during visit 2:

  1. Abnormal otoscopy as defined by less than 90% of the tympanic membrane visible (cerumen ear plug, ear drum perforation, …)
  2. Conductive hearing loss defined by an air-bone threshold gap of 10 dB or greater based on the average of frequencies 0.5, 1, 2, and 4 kHz, and abnormal hearing thresholds (greater than 20 dB HL) for these frequencies.
  3. Abnormal tympanogram (other type than A)
  4. Asymmetric hearing loss: more than 15 dB difference in the pure-tone average (PTA) air conduction (for MCI patients and control group only)
  5. Single-sided deafness (SSD)
  6. Cophosis (PTAv > 120 dB)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
309 participants (estimated)

Study arms

  • Other
    Control group

    Control population

    Other: Thorough Hearing assessment

  • Experimental
    Amnestic MCI Group

    Patients with amnestic mild cognitive impairment

    Other: Thorough Hearing assessment

  • Experimental
    Parkinson Group

    Patient with parkinson's disease

    Other: Thorough Hearing assessment

Interventions

  • OtherThorough Hearing assessment

    Otoscopy Tympanometry Tonal audiometry (air and bone conduction) Vocal audiometry (in silence and in noise) Distorsion Products of OtoAcoustic Emissions (DPOAE) Middle Ear Muscle Reflex (MEMR) Auditory Brainstem Response (ABR) Electrocochleography (EcochG)

06

What researchers measure

Primary outcomes

  1. Prevalence of hidden hearing loss

    Percentage of population in each group that displays normal audiometric thresholds (0.5-4kHz) and impaired speech-in-noise intelligibility

    Time frame: within one month from inclusion

Secondary outcomes

  1. Prevalence of sensorineural hearing loss

    Percentage of patients in each group with elevated hearing thresholds (0.5-4kHz)

    Time frame: within one month from inclusion

  2. Grade of sensorineural hearing loss

    As defined by BIAP criteria : \]20-40 dB nHL\] = mild ; \]40 - 55\] = moderate ; \]55 - 70\] = moderately severe ; \]70 - 90\] = severe ; \]90 - 120\] = profound ;

    Time frame: within one month from inclusion

Other outcomes

  1. Explore auditory signatures in neurodegenerative disease patients

    Determine combination of auditory results that could be discriminatory of patient population versus control group

    Time frame: one month from inclusion

  2. Identify potential biomarkers of cochlear synaptopathy

    correlations between specific auditory findings and disease parameters

    Time frame: one month from inclusion

07

Study locations

4 of 4 sites recruiting
  • CHU Gui de Chauliac
    Montpellier, 34080, France
    Recruiting
    • Audrey GABELLE, MD · Principal investigator
  • CHU Nice
    Nice, 06000, France
    Recruiting
    • Guillaume SACCO, MD · Principal investigator
    • Aurélie MOUTON, MD · Sub investigator
    • Caroline GIORDANA, MD · Sub investigator
  • CHU Carémeau
    Nîmes, 30900, France
    Recruiting
    • Cassiana TRANDAFIR, MD · Principal investigator
    • Giovanni CASTELNOVO, MD · Sub investigator
  • Hospices Civils de Lyon, Hôpital des Charpennes
    Villeurbanne, 69100, France
    Recruiting
    • Sophie DAUTRICOURT, MD · Principal investigator
    • Antoine GARNIER CRUSSARD, MD · Sub investigator
    • Fannie BRETELLE, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 69 industry-sponsored interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's planned 21 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Jul 24, 2025
StartActual
Mar 24, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07083089
Lead sponsor
Cilcare SAS
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Mar 24, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 9, 2025

Study contacts

Laura BREDA, Master's degree
Contact
laura.breda@cilcare.com
+33769042226
Mathieu SCHUE, PhD
study director · Cilcare SAS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion